Remember meForgot password?
    Log in with Twitter
Press Release

Roche Canada announces a significant investment in pharmaceutical development in Ontario

Canada NewsWire

OTTAWA, Aug. 16, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to complement the announcement made earlier today by Hoffmann-La Roche Limited (Roche Canada) of an investment of over $190 million to establish a major global pharmaceutical development site in Mississauga, Ontario. This project is supported by a $7.79 million investment from the Ontario Ministry of Economic Development and Trade allowing for the creation of 200 new highly-skilled jobs and the strengthening of local economies in this province.

"Today's joint announcement reflects a shared commitment by Canada's research-based pharmaceutical industry and the Government of Ontario to build long-term economic benefits and international leadership in life sciences and pharmaceuticals in Ontario.

"The chance to improve patient health and quality of life through research and innovation is what motivates all those active in the life science community. In Ontario, this is reflected in lasting strategic partnerships that include not only government and industry, but also universities, health care professionals and the research-based pharmaceutical community.

"This major investment from Roche Canada will attract some of the best and brightest researchers from around the world and will firmly establish Roche Canada as a global hub and research leader for life sciences and pharmaceuticals. It will also provide opportunities for collaboration with local researchers in established institutions, clinical research organizations and clinical trial networks.

"This pharmaceutical development site, one of six in the world, will allow researchers to manage operations for all stages of global clinical trial research. The impacts on the research community and patients will be far reaching and will showcase Ontario as a place to do quality clinical research.

"Over the next five years, leadership positions in global trial and data management will be assumed by the new Roche Canada pharmaceutical development site. The Canadian facility will provide global leadership and coordination for research and development that will take place through its substantial affiliate R&D network in more than 60 countries.

"It is by working together that we can consolidate the position of Ontario and Canada as potential world leaders in the provision of health care solutions to people across the country and throughout the world. However, further improvements to Canada's intellectual property and access regimes would greatly facilitate the attraction of additional life sciences investments in Canada by the innovative pharmaceutical sector that will benefit Canadian patients and the economy. "

About Rx&D
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

For more information: visit:

About Roche Canada
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and is a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

Roche Canada was founded in 1931. The company employs approximately 900 people across the country, with its pharmaceuticals head office located in Mississauga, Ontario and diagnostics division based in Laval, Quebec. Roche Canada is actively involved in local communities, investing in charitable organizations and partnering with healthcare institutions across the country.

For more information, visit